Manhattan Scientifics

Manhattan Scientifics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Manhattan Scientifics (MHTX) as of Nov 10, 2026 is 16.31 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 12.78 % — a change of 27.57% (higher).

FCF Conversion

16.31 %

YoY

27.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Manhattan Scientifics is 2023 16.31 % . FCF Conversion Rate (FCF/EBITDA) of Manhattan Scientifics was 2022 12.78 % . It decreases by 27.57% higher compared to the previous year.

The Manhattan Scientifics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
74.84 USD
Jan 1, 2017
-51.68 USD
Jan 1, 2018
8.23 USD
Jan 1, 2019
26.19 USD
Jan 1, 2020
-9.09 USD
Jan 1, 2021
11.57 USD
Jan 1, 2022
12.78 USD
Jan 1, 2023
16.31 USD
The Manhattan Scientifics FCF Conversion history
YEARFCF ConversionYoY
16.31 %+27.57%
12.78 %+10.50%
11.57 %-227.32%
-9.09 %-134.70%
26.19 %+218.13%
8.23 %-115.93%
-51.68 %-169.06%
74.84 %+89.74%
39.44 %-41.63%
67.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Manhattan Scientifics Stock analysis

What does Manhattan Scientifics do? Manhattan Scientifics Inc is an innovative company that operates in the world of science and technology. The company was founded in 1994 by Marvin Maslow and is based in New York City. It primarily focuses on developing advanced technologies in the fields of materials science, biotechnology, and medical technology. The business model of Manhattan Scientifics Inc is based on the discovery and development of new technologies, which are then licensed or sold. The company specializes in technology development and works closely with scientific institutions and researchers around the world. In the past, the company has collaborated closely with NASA and the Los Alamos National Laboratory, and has been able to bring several successful products to market. The various divisions of Manhattan Scientifics Inc include nanotechnology, biotechnology, and medical technology. In the field of nanotechnology, the company has developed advanced technologies for the production of ultralight, highly strong materials. These materials are used in aerospace, construction, and other industries where lightweight and durable materials are needed. The biotechnology division of Manhattan Scientifics Inc focuses on the development of novel therapies for cancer and other diseases. The company has successfully developed a new cancer therapy based on magnetic nanoparticles. These nanoparticles are introduced into the body and attach to cancer cells. They are then attracted and killed by an external magnetic field. Medical technology is another important division of Manhattan Scientifics Inc. The company has developed advanced technologies for the production of medical devices that provide more precise surgeries and treatments. One of Manhattan Scientifics Inc's successful innovations is a device that can precisely target tumors with high-energy radiation to destroy them. Manhattan Scientifics Inc has brought several successful products to market in the past. One example of such a product is the Greenshift Corporation System, which helps reduce emissions from airplanes. The company has also had successful collaborations with NASA on various projects, including the development of super-lightweight carbon fiber components. Overall, Manhattan Scientifics Inc is an innovative company that specializes in the development of new technologies. The company has successfully worked in various fields, including nanotechnology, biotechnology, and medical technology. Its business model is based on the discovery and development of new technologies, which are then licensed or sold. Through its collaborations with scientific institutions and researchers around the world, the company has developed and brought several successful products to market. Manhattan Scientifics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Manhattan Scientifics stock

FCF Conversion Rate (FCF/EBITDA) of Manhattan Scientifics is 16.31 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Manhattan Scientifics changed from 12.78 % to 16.31 %, representing a 27.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Manhattan Scientifics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Manhattan Scientifics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Manhattan Scientifics

All Key Metrics — Manhattan Scientifics